MedPath

Novel Agents for Treatment of High-risk COVID-19 Positive Patients

Phase 2
Terminated
Conditions
COVID
Sars-CoV2
Interventions
Registration Number
NCT04374019
Lead Sponsor
Susanne Arnold
Brief Summary

This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in will be devoid of additional moderate to severe toxicities, will prevent clinical deterioration, and will improve viral clearance in high risk individuals.

Detailed Description

Coronavirus Disease 2019 (COVID-19) is a highly contagious disease, caused by a novel enveloped RNA beta-coronavirus, also known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The first case of this unprecedented outbreak "pneumonia of unknown etiology" was reported in Wuhan City, Hubei Province, China on December 8th, 2019 and reported to the World Health Organization (WHO) on December 31st, 2019. WHO declared a COVID-19 global emergency on January 30, 2020, and then categorized the outbreak as a pandemic on March 11, 2020. As of April 22, 2020, more than 2,628,894 confirmed cases of COVID-19 worldwide and 182,740 people globally have died from COVID-19 since it emerged in China, according to the data from Johns Hopkins University.

While the majority of patients with COVID-19 develop mild or uncomplicated illness, approximately 20-30% of hospitalized patients have required intensive care support and 5% of those have multi-organ failure or shock. The case fatality rate ranges from 1 to 4% and it is higher among those with pre-existing comorbid conditions such as cardiovascular disease, diabetes mellitus, obesity, chronic respiratory disease, hypertension and cancer. The vast majority of patients present with fever (83-99%), cough (59-82%), fatigue (44-70%), anorexia (40-84%), shortness of breath (31-40%), sputum production (28-33%), myalgias (11-35%). Less than 10% of patients will present with headache, confusion, rhinorrhea, sore throat, hemoptysis, vomiting, or diarrhea. Anosmia or ageusia proceeding the onset of respiratory symptoms has been anecdotally reported.

To date, treatments for COVID-19 in high risks individuals remain experimental and therapeutic strategies to deal with the infection are at best supportive, with prevention aimed at reducing transmission in the community as the best weapon. No proven therapies have been demonstrated to prevent the progression of COVID-19 to severe illness and this is a critical unmet need for high-risk individuals and warrants study. Recently, the Infectious Disease Society of America has made recommendations for the treatment of patients with COVID-19, focusing on inpatient care, and recommending randomized trials where possible as the best step to improve treatment outcomes and to increase our understanding of this coronavirus pandemic. Discoveries in this area may inform clinicians on effective treatment for low-risk individuals who progress to severe illness, as well.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
13
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm D: Camostat MesilateCamostat MesilateCamostat Mesilate
Arm E: Artemesia annuaArtemesia annuaArtemesia annua tea or coffee
Arm C: IvermectinIvermectinIvermectin
Arm F: ArtesunateArtesunateArtesunate
Primary Outcome Measures
NameTimeMethod
Clinical Deterioration14 days

Number of patients experiencing clinical deterioration. Clinical deterioration is defined as a less than a 2-point change from the initial COVID 7-Point Ordinal Outcomes Scale within 14 days from the study start. This scale ranges from 1-7. Lower scores indicate worse outcomes (death); higher scores indicate fewer symptoms and better outcomes.

Secondary Outcome Measures
NameTimeMethod
Change in Viral Load40 days

The change in (clearance of) viral RNA will be measured by PCR testing at days 1, 14, 28, and 40 days.

Progression to ICU Care or Ventilation28 days

Percentage of patients requiring ICU admission or ventilation.

Number of Participants Who Had a Change in Clinical Status Measured by Decrease in COVID 7-point Ordinal Scale14 days

Number of participants who died or had greater than a 2-point decrease in COVID 7-Point Ordinal Outcomes Scale from Day to Day 14.

COVID 7-point ordinal outcomes scale:

1. Death

2. Hospitalized on invasive mechanical ventilation or ECMO

3. Hospitalized on non-invasive ventilation or high flow nasal cannula

4. Hospitalized on supplemental oxygen

5. Hospitalized not on supplemental oxygen

6. Not hospitalized with limitation in activity (continued symptoms)

7. Not hospitalized without limitation in activity (no symptoms)

Mortality14 days

Percentage of patients who have died by day 14.

Rate of Organ Failure28 days

Number of patients that experienced severe respiratory or other organ failure.

Heart Function28 days

Proportion of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes, or abnormalities including severe QTc prolongation of \> 500 ms.

Rate of Severe Adverse Events14 days

Percentage of patients experiencing severe adverse events, defined as grade 3 non-hematologic or greater by DMID Toxicity Scale for Determining Severity of Adverse Events.

Number of Patients That Required Oxygen Supplementation28 days

Number of patients that required oxygen supplementation during study treatment Days 1-28

Number of Patients That Required Mechanical Ventilation28 days

Number of patients that required mechanical ventilation during the study period. Days 1-28

Number of Patients Who Required Vasopressors28 days

Number of patients who required vasopressor treatment Days 1 to 28

Number of Patients Who Required ICU Services28 days

Number of patients who required ICU services during study treatment Days 1-28.

Number of Patients That Required Hospitalization28 days

Number of patients that required hospitalization during study treatment

Trial Locations

Locations (1)

University of Kentucky Markey Cancer Center

🇺🇸

Lexington, Kentucky, United States

© Copyright 2025. All Rights Reserved by MedPath